CURITY Pharma

Medical Cannabis

The Science of Cannabinoids

Fundamental Biological Signalling Network

The Endocannabinoid System (ECS) is a complex biological signalling network present throughout the human body. It contributes to the maintenance of physiological homeostasis by regulating communication between cells in multiple organ systems, including the nervous, immune, gastrointestinal, endocrine, and metabolic systems. The ECS comprises three principal components: endocannabinoids (endogenous signalling molecules), cannabinoid receptors, and the enzymes responsible for their synthesis and degradation. Together, these components help coordinate cellular responses to changing physiological conditions and support normal biological function. Since its discovery in the late twentieth century, the ECS has become one of the most extensively studied signalling systems in biomedical research and continues to provide important insights into human physiology and potential therapeutic innovation.

Homeostasis: A Dynamic Biological Process

Maintaining physiological homeostasis is essential for normal human function. The Endocannabinoid System (ECS) acts as a widespread lipid signalling network that modulates cellular communication throughout the nervous, immune, endocrine, gastrointestinal, and metabolic systems. By responding to changes in physiological conditions, the ECS contributes to the fine regulation of numerous biological processes, supporting the body’s ability to adapt and maintain internal balance. Since its discovery, the ECS has become one of the most extensively investigated signalling systems in biomedical research, with growing interest in its role in physiology and disease.

The Building Blocks of the Endocannabinoid System

The Endocannabinoid System (ECS) is an endogenous lipid signalling network built upon three fundamental components: endogenous cannabinoids, cannabinoid receptors, and metabolic enzymes. Endocannabinoids act as signalling molecules, cannabinoid receptors mediate cellular responses, and specialized enzymes tightly regulate the synthesis and degradation of these endogenous ligands. Together, these components form an integrated communication system that contributes to the regulation of numerous physiological processes and the maintenance of homeostasis. Understanding the interaction between these key components has become central to modern cannabinoid science and pharmaceutical research.

Endocannabinoids: The Body’s Endogenous Signaling Molecules

Endocannabinoids are naturally produced lipid signalling molecules that enable communication within the Endocannabinoid System (ECS). Synthesized on demand in response to physiological stimuli, they bind primarily to CB1 and CB2 cannabinoid receptors to regulate cellular signalling across the nervous, immune, gastrointestinal, endocrine, and metabolic systems. The two principal endocannabinoids—anandamide (AEA) and 2-arachidonoylglycerol (2-AG)—work together to help maintain physiological homeostasis through precisely controlled biological signalling. Their discovery transformed our understanding of human physiology and established the scientific foundation of modern cannabinoid research.:

Cannabinoid Receptors

CB1 Receptors

CB1 receptors are among the most abundant G-protein-coupled receptors in the human nervous system. They are highly expressed in the brain and are also found in peripheral tissues including the gastrointestinal tract, liver, skeletal muscle, adipose tissue, and other organs.

Research suggests CB1 receptors participate in the regulation of:

CB2 Receptors

CB2 receptors are predominantly associated with cells of the immune system and are widely distributed in immune-related tissues such as the spleen, thymus, and circulating immune cells.

Important note: This page is educational and does not provide medical advice. Medical cannabis products should only be used where legally available and prescribed or recommended by an appropriately qualified healthcare professional.

References

  1. Di Marzo V. The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery. 2004;3(9):771–784. doi:10.1038/nrd1495.
  2. Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2021;6(6):607–615. doi:10.1016/j.bpsc.2020.10.007.
  3. Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences. 2018;19(3):833. doi:10.3390/ijms19030833.
  4. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacological Reviews. 2002;54(2):161–202. doi:10.1124/pr.54.2.161.
  5. Pertwee RG. Cannabinoid pharmacology: The first 66 years. British Journal of Pharmacology. 2006;147(S1):S163–S171. doi:10.1038/sj.bjp.0706406.
  6. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press; 2017. doi:10.17226/24625.
  7. Maccarrone M, Bab I, Bíró T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends in Pharmacological Sciences. 2015;36(5):277–296. doi:10.1016/j.tips.2015.02.008.
  8. Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the Expanded Endocannabinoid System in Neurological Disorders. Nature Reviews Neurology. 2020.
  9. Mechoulam R, Shvo Y. Hashish—I. The structure of cannabidiol.Tetrahedron. 1963;19(12):2073–2078. doi:10.1016/S0040-4020(01)80900
  10. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish.Journal of the American Chemical Society. 1964;86(8):1646–1647. doi:10.1021/ja01062a046
  11. Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 1988;34(5):605–613.
  12. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA.Nature. 1990;346(6284):561–564. doi:10.1038/346561a0.
  13. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.Science. 1992;258(5090):1946–1949. doi:10.1126/science.1470919.
  14. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–65. doi:10.1038/365061a0.
  15. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology. 1995;50(1):83–90. doi:10.1016/0006-2952(95)00109-D.
  16. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications. 1995;215(1):89–97. doi:10.1006/bbrc.1995.2437.